41 results about "Hypromellose phthalate" patented technology

The invention relates to a dirithromycin (DRM) enteric preparation with hydroxypropyl methylcellulose phthalate (HPMCP) being the framework material of drug-containing core and the coating material of an enteric coating layer. The enteric preparation has the advantages that the drug content is higher, the drug dissolution rate is less affected by the coating material, the preparation cost is low and the preparation process is simple.

The invention discloses an ursolic acid solid dispersion and a preparation method thereof. The formula of the ursolic acid solid dispersion comprises ursolic acid and a carrier material; the mass ratio of the ursolic acid to the carrier material is 1:2 to 1:20; and the carrier material is one or more of PEG6000 (polyethylene glycol 6000), povidone k29/33, hypromellose E5, polyving alcohol, poloxamer 68, GELUCIRE 50/13, polyacrylic resin EPO, polyacrylic resin L 100-55, povidone-vinyl alcohol, hypromellose AS-HG, hypromellose AS-LG, hypromellose AS-MG, low substituted hypromellose, hypromellose phthalate, cellulose acetate phthalate, glucan, polyoxyethylene, polyoxyethylene stearates and polyvinyl acetate phthalate. The preparation method comprises the following steps: dissolving the ursolic acid and the carrier material into an organic solvent according to the formula; removing the organic solvent; and grinding. The ursolic acid solid dispersion has good solubility and has high bioavailability.

The invention relates to a preparation method of taste-masked suspension granules of Gegenqinlian decoction. The preparation method comprises the following steps of 1, taking appropriate amounts of dispensing granules of three traditional Chinese medicines comprising radix puerariae, coptis chinensis and scutellaria baicalensis and respectively carrying out coating processes in a fluidized bed through adopting one or more polymers as coating materials to obtain coated granules for next use, 2, taking an appropriate amount of at least one suspending agent, mixing uniformly the at least one suspending agent and radix glycyrrhizae preparata dispensing granules, then adding an appropriate amount of an adhesive into the mixture to prepare into granules by a wet method, drying the prepared granules in an oven, and then spraying an appropriate amount of an ethanol solution as an aromatic to obtain suspending agent-containing radix glycyrrhizae preparata dispensing granules after ethanol is volatilized, and 3, weighing appropriate amounts of the suspending agent-containing radix glycyrrhizae preparata dispensing granules and the coated granules containing radix puerariae, coptis chinensisand scutellaria baicalensis, mixing well, and carrying out sub-packaging to obtain the taste-masked suspension granules of Gegenqinlian decoction, wherein the one or more polymers as coating materials are selected from enteric-coated polyacrylic resin, hypromellose acetate succinate and hydroxypropyl methylcellulose phthalate. The invention provides the preparation method of the taste-masked suspension granules of Gegenqinlian decoction. The preparation method is also suitable for taste masking of a traditional Chinese medicine with a bitter taste or a fishy smell.

The invention discloses an aprepitant oral pharmaceutical preparation. The aprepitant oral pharmaceutical preparation comprises 15wt%-25wt% of aprepitant, 45wt%-75wt% of hydroxypropyl methylcellulose phthalate/hydroxypropyl methylcellulose acetate succinate, 10wt%-25wt% of microcrystalline cellulose, lactose or mannitol, 2wt%-8wt% of low-substituted hydroxypropyl cellulose as well as croscarmellose sodium and/or crospovidone, 0-2wt% of silicon dioxide and/or talc and 0-2wt% of magnesium stearate. The pharmaceutical preparation can be prepared in a form of tablets or capsules andhas high stability and good bioavailability.

A rebeprazole sodium enteric-coated tablet comprises, by weight, 65-125 parts of tablet core, 10-40 parts of isolation layer and 80-170 parts of enteric-coated layer, wherein filler is one or more of microcrystalline cellulose, lactose and mannitol, stabilizer is one or more of magnesium oxide and anhydrous sodium carbonate, disintegrating agent is one or more of polyvinyl pyrrolidone, cross-linking sodium carboxymethyl cellulose and lauryl sodium sulfate, lubricating agent is one or two of talcum powder and magnesium stearate, binder is the anhydrous ethanol solution of crospovidone or the aqueous solution of hydroxypropyl methylcellulose, the isolation layer is one or two of magnesium oxide and ethyl cellulose, and the enteric-coated layer is one or more of hydroxypropyl methylcellulose phthalic acid ester, enteric-coated acrylic resin, cellulose acetate phthalic ester, talcum powder and 93F19255 type coating agent. A preparation process of the rebeprazole sodium enteric-coated tablet is simple, low in equipment requirement, high in yield, and controllable in product quality. The dissolution rate of the rebeprazole sodium enteric-coated tablet is highly consistent with the release behavior of originally-developed drugs, and the rebeprazole sodium enteric-coated tablet is good in stability.

A new compound composition that is free of a side effect to a liver and used for alleviating the toxicity of an acetaminophen (APAP) medicament to the liver. The compound composition comprises (a) a pharmaceutically effective amount of acetaminophen and (b) a frequently-used safe and pharmaceutically acceptable excipient that can be combined with one or more than two medicaments that can reduce the toxicity of a drug via liver enzyme CYP2E1 metabolism to the liver. The compound is selected from the following group: Tween 20, microcrystalline cellulose, dicalcium phosphate, polyoxyethylene 23 lauryl ether, saccharin, mannitol, polyoxyethylene alkyl ether, sucralose, pyrrolidone, sodium starch glycolate, acrylic resin S100, carboxymethyl cellulose sodium, polyoxyethylene polyoxypropylene, menthol, low-substituted hydrocarbon propyl cellulose, pregelatinized starch, Dextrates NF hydrated, citric acid, polyoxyethylene castor oil, colloidal silica, polyethylene glycol monostearate aliphatic ester, sorbic acid, lemon oil, hydroxypropyl cellulose, sorbitol, acesulfame potassium, hypromellose phthalate, lactose monohydrate, maltodextrin, Brij 58, Brij 76, Tween 80, Tween 40, PEG 400, PEG 4000, PEG 2000, and the like, so as to reduce the side effect of the toxicity caused by acetaminophen to the liver.

The invention relates to the pharmaceutical field and discloses a cilostazol sustained-release capsule compound and a preparation method thereof. The sustained-release capsule compound comprises a medicinal hollow capsule body and contents arranged in the medicinal hollow capsule body. The contents comprise cilostazol, a hydroxypropyl methylcellulose phthalate sustained-release framework material, a retardant, an adhesive, a filler, an antisticking agent and a lubricating agent. Hydroxypropyl methylcellulose phthalate is used as the framework sustained-release material and is a product obtained by performing an esterification reaction between hydroxypropyl methylcellulose and phthalic anhydride in acetic acid with sodium acetate serving as a catalyst. Molecules have carboxyl negative charge intermolecular repulsion under a carboxyl alkaline environment, so that twinned macromolecules are stretched to be dissolved, and enteric solubility is achieved. The absorption of the cilostazol by the upper gastrointestinal tract can be reduced while the absorption of the cilostazol by the lower gastrointestinal tract is improved. Adverse drug reactions such as headaches, head heaviness and tachycardia caused by sudden increase of the drug concentration are overcome. In addition, the cilostazol sustained-release capsule compound is taken only one time per day, so that the adaptability of patients is improved.

The invention belongs to the technical field of medicinal preparation processing, and particularly relates to a sodium bicarbonate enteric capsule and a preparation method thereof. The preparation method of the sodium bicarbonate enteric capsule comprises the following steps: adding a capsule shell material suitable for alkaline contents into water, heating and stirring to obtain a solution, and dipping with glue to obtain a hollow capsule shell; dipping the hollow capsule in an enteric coating solution, and drying to obtain an enteric hollow capsule shell; filling the content containing sodium bicarbonate, coating a sealing material solution at the sleeved part of the capsule, and drying to obtain the sodium bicarbonate enteric capsule. The capsule shell material suitable for the alkalinecontents is prepared from the following raw materials in parts by weight: 10-20 parts of hydroxypropyl methyl cellulose phthalate, 1-2 parts of curdlan and 0.5-1.5 parts of xanthan gum. According tothe invention, the enteric hollow capsule is filled with the alkaline contents, so adverse reactions of the stomach can be avoided, and the effects of neutralizing uric acid and protecting the intestinal tract can be more effectively realized; and compared with the coating by a spraying technology, the enteric hollow capsule has less influence on the contents.

The invention discloses a duloxetine pharmaceutical composition. The duloxetine pharmaceutical composition comprises (1) a pellet loaded with a certain amount of duloxetine; and (2) an enteric layer consisting of two types of hydroxypropylmethyl cellulose phthalate different in pH solubility, wherein the enteric layer coats the pellet. According to the pharmaceutical composition, the polymer hydroxypropylmethyl cellulose phthalate (HPMCP) with different levels of pH solubility is used, and adding ammonia for neutralization is not needed, so that the process is shortened, the reaction between the enteric layer and active substances of the duloxetine on the pellet is greatly reduced, and stability is increased; in addition, different HPMCP forms the enteric layer, so that the duloxetine is prevented from being damaged by the acidic condition of a stomach, and the duloxetine is released in a gastrointestinal tract (GIT) with relatively high pH, for example, in a small intestine, and thus,accurate release of the drug at a target part is facilitated, and the risk of dose dumping of the drug within an initial time interval is greatly lowered.

There is provided a method for producing hypromellose phthalate (HPMCP), the method not requiring any special device, and facilitating removal of impurities. More specifically, there is provided a method for producing HPMCP, including an esterification step of esterifying hypromellose with a carboxybenzoylating agent in the presence of an aliphatic carboxylic acid to obtain a reaction product solution containing HPMCP; a precipitation step of precipitating the HPMCP by mixing the reaction product solution with water to obtain a suspension of the precipitated HPMCP; a neutralization step of neutralizing the suspension with a basic substance to obtain a neutralized suspension; and a washing step of washing the HPMCP contained in the neutralized suspension to obtain the washed HPMCP.